Tenon Medical Announces Successful Completion of Initial Cases with New SImmetry(R)+ SI Joint Fusion System
Rhea-AI Summary
Tenon Medical (NASDAQ:TNON) announced completion of initial clinical procedures using its new SImmetry+ SI Joint Fusion System on December 4, 2025, with cases at Centers of Excellence in Florida, Arizona, Ohio, and Texas.
The minimally invasive lateral system uses 3D-printed titanium implants, joint decortication, and a bone graft delivery system, cleared for use with one to three implants. Tenon cites published 12-month EvoluSIon data (250 patients): 68.7% radiographic fusion at 12 months and a 57.1% decrease in pre-operative opioid use.
Tenon is conducting a controlled early-access rollout with select SI fusion physicians to gather procedural feedback ahead of broader commercial launch.
Positive
- 68.7% radiographic fusion at 12 months (EvoluSIon, 250 patients)
- 57.1% decrease in pre-operative opioid use at 12 months
- Initial clinical implants completed across four states during early-access rollout
Negative
- Commercial availability limited to a controlled early-access rollout pending broader launch
- Published fusion rate of 68.7% indicates not all patients achieved radiographic fusion at 12 months
News Market Reaction
On the day this news was published, TNON declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While TNON was down 2.61%, peers showed mixed action: RSLS gained 29.8%, while PAVM, SINT, and XAIR were modestly negative and DHAI was flat. This points to stock-specific trading rather than a coordinated medical devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Product launch update | Positive | +0.0% | Initial clinical use of SImmetry+ SI Joint Fusion System in multiple centers. |
| Nov 14 | PIPE financing close | Negative | +0.0% | Closed $2.85M at-the-market PIPE with shares and warrants issued. |
| Nov 13 | Q3 2025 earnings | Positive | -8.5% | Reported 32% YoY revenue growth and higher margins but wider net loss. |
| Nov 11 | PIPE pricing | Negative | +0.0% | Priced $2.85M PIPE with common shares and three-year warrants. |
| Nov 03 | Earnings timing | Neutral | -0.8% | Announced timing and call details for Q3 2025 financial results. |
Recent TNON news often saw muted or negative price reactions: a positive Q3 report coincided with an 8.53% drop, while financing and product updates generally produced flat trading.
Over the last few months, Tenon reported growing Q3 2025 revenue of $1.2M with a 66% gross margin and continued net losses of $3.3M. The company expanded its SI joint portfolio through the SiVantage acquisition and launched Catamaran SE and SImmetry+ initiatives. It also completed an at-the-market PIPE raising about $2.85M via 2,217,904 shares plus warrants, alongside insider purchases disclosed in multiple Form 4s. Today’s SImmetry+ initial-case announcement builds on this multi-product sacro-pelvic fusion strategy and prior clinical evidence (EvoluSIon study).
Market Pulse Summary
This announcement highlights initial real-world use of Tenon’s SImmetry+ SI Joint Fusion System, backed by 12‑month EvoluSIon data in 250 patients with 68.7% radiographic fusion and a 57.1% decrease in opioid use. It extends a multi-approach sacro‑pelvic strategy alongside Catamaran, following recent portfolio-expanding acquisitions and PIPE financing. Investors may watch future updates on broader commercial rollout, procedure volumes, and how these technologies affect revenue growth and margins alongside ongoing capital needs.
Key Terms
3D-printed titanium implants technical
bone graft medical
arthrodesis medical
radiographic fusion medical
computed tomography (CT) medical
AI-generated analysis. Not financial advice.
~ Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas ~
~SImmetry+ combines 3D-printed titanium implants, a robust joint decorticator, and a streamlined bone graft delivery system to offer treatment solutions aligned with established fusion principles ~
~ Immediate revenue impact opportunity while significantly advancing Tenon's competitive position in redefining SI joint fusion with a multi-approach portfolio in rapidly expanding sacro-pelvic market ~
LOS GATOS, CA / ACCESS Newswire / December 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced the completion of the first clinical procedures utilizing the Company's new SImmetry+ SI Joint Fusion System. Ali Araghi, DO, Orthopedic Spine Surgeon in Phoenix, Arizona, Brian Fiani, DO Board Certified Neurosurgeon in Tampa, FL., Kraig Kristof, MD, Orthopedic Spine Surgeon in Toledo, OH., and Sunil Panchal, MD Interventional Pain physician in Tampa, FL. were among the first physicians to successfully implant the SImmetry+ system in patients diagnosed with sacroiliac joint dysfunction.
The SImmetry+ SI Joint Fusion System is a next-generation, minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles-including joint decortication, bone graft placement, and rigid fixation-with the goal of achieving a true biological fusion across the SI joint. The system features 3D-printed titanium implants engineered to effectively stabilize the SI Joint by incorporating a self-drilling, self-tapping, and self-harvesting design to streamline implantation and enhance bone preparation and fusion. The system is cleared for use with one to three implants, allowing physicians flexibility based on patient anatomy and pathology.
Initial physician use of SImmetry+ is currently underway through a controlled, early-access rollout with a select group of experienced SI fusion physicians as listed above. These early adopters will provide important procedural and clinical feedback on the implant design, technique, and instrumentation to support a broader commercial launch readiness. Additional alpha cases are currently being scheduled at multiple Centers of Excellence across the United States.
Clinical evidence supporting the SImmetry+ system includes 12-month outcomes from the EvoluSIon study, published in the International Journal of Spine Surgery. Among 250 treated patients, the procedure demonstrated a strong safety profile and resulted in meaningful reductions in pain and improvement in quality-of-life measures. Patients also experienced a
"The first successful clinical use of SImmetry+ represents another meaningful milestone in Tenon's mission to advance sacro-pelvic fusion options for physicians and their SI joint patients," said Steve Foster, President and Chief Executive Officer of Tenon Medical. "Ongoing feedback from our physician advisors guides us in refining every aspect of the system and workflow. These technologies only reach their full potential with world-class clinical insight, and we are deeply grateful for the expertise our advisors bring. SImmetry+ combines proven orthopedic fusion principles with modern implant and instrument design to support a true fusion approach. Early clinical feedback reinforces our belief that this next-generation technology can further accelerate adoption and strengthen our growing sacro-pelvic portfolio."
The SImmetry+ and Catamaran® SI Joint Fusion System are the foundation of Tenon's growing portfolio of advanced technologies. Together, these platforms uniquely position the Company with multiple surgical approaches-lateral and inferior-posterior-both designed to be minimally invasive, enable authentic arthrodesis and supported by robust clinical evidence, including the published prospective Mainsail™ and EVoluSIon SI joint fusion studies. These differentiated technologies will enable physicians to customize treatment plans for their patients with an innovative portfolio that spans SI joint, spinal fusion, revision surgery and deformity adjuncts - each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multi-approach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.
Safe Harbor
This press release contains "forward-looking statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," "aims," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
IR Contact:
Shannon Devine / Rory Rumore
203-741-8811
MZ North America
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Tenon Medical (TNON) announce on December 4, 2025 about SImmetry+?
What clinical evidence supports Tenon’s SImmetry+ system for TNON investors?
How many implants does the SImmetry+ system allow per procedure for TNON patients?
Where were the first SImmetry+ procedures performed under TNON’s early-access program?
Will SImmetry+ immediately drive revenue for Tenon (TNON)?
What are the next steps before SImmetry+ is widely available to TNON shareholders?
